Strategy increased its Bitcoin holdings by 811 BTC, spending $65.5 million funded through $164 million raised from MSTR stock sales. This raised its total Bitcoin treasury to 849,327 BTC, valued at about $66 billion. Despite a recent dip in Bitcoin prices following a major Binance hack, the company maintains significant unrealized gains and continues to hold substantial cash reserves and preferred stock repurchase capacity. This move signals ongoing confidence in Bitcoin despite market volatility.
Strategy's Bitcoin treasury reached about 849,327 BTC, valued near $66 billion, as of November 2, 2026. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Nov 02, 2026 19:42 WIB: out of 50 major cryptocurrencies priced on Pluang, 7 rose and 42 fell. Notable movers include BAT at Rp2.394 with a 1-day change of -5.58% and Pluang order activity showing 73% Sell / 27% Buy, CRV at Rp4.969 down 4.46% with 57% Sell / 43% Buy, and LUNC at Rp0,75 down 4.34% with nearly balanced order activity at 51% Sell / 49% Buy.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
